- Argus raises IQVIA Holdings Inc. IQV price target from $110 to $112, says contract research organizations will benefit from “steady biopharmaceutical funding and a healthy backlog”; Firm raises 2018 adj. EPS forecast to reflect Q4 earnings surprise and addition of new multi-year contracts.
- Wedbush upgrades Comerica Incorporated CMA to Outperform, says margin expansion, potential resumption of loan growth, and above average capital returns should drive EPS growth over next two years.
- Citi reiterates Buy rating on Monster Beverage Corp MNST and maintains U.S. Focus List status, citing “strong trends” in global energy drink category; “MNST continues to gain share globally, and still has plenty of runway ahead."
- Chardan raises Regenxbio Inc RGNX price target from $85 to $90 on news co.'s partner, AveXis, was bought by Novartis, believing this could support M&A interest in RGNX & suggesting "consensus is underestimating the impact of AVXS-101 royalites on Regenxbio."
- Cantor Fitzgerald double downgrades NewLink Genetics Corp NLNK after Incyte's failed trial of a therapy similar to NewLink’s indoximod.
- Loop Capital Markets upgrades Rent-A-Center, Inc. RCII from Sell to Hold and raises price target from $6 to $9 based on widespread media reports of multiple bids for the company; Firm says Q1 performance may indicate to potential acquirers that business has “bottomed,” making a deal more attractive.
- 'Best-In-Class' Bridgewater Bancshares Inc BWB has strong credit quality, 20 percent upside potential, DA Davidson says in bullish initiation.
See Also:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in